C4 Therapeutics, Inc. (CCCC): Depreciation & Amortization
$1.96M
Year ended 2025-12-31
+5.3%
3-year compound annual growth
+3.9%
5-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.96M | +7.8% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $1.82M | -3.3% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $1.88M | +12.2% | 2025-02-27, From 2023-01-01 |
| 2022-12-31 | $1.68M | +12.3% | 2024-02-22, From 2022-01-01 |
| 2021-12-31 | $1.49M | -7.7% | 2023-02-23, From 2021-01-01 |
| 2020-12-31 | $1.62M | +1.4% | 2022-02-24, From 2020-01-01 |
| 2019-12-31 | $1.59M | n/a | 2022-02-24, From 2019-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $1.96M | +7.8% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $1.28M | +60.4% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $1.47M | -56.9% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $8.31M | +12.7% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $3.96M | -22.4% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $4.62M | +14.3% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $1.38M | -16.0% |
| Alector, Inc. (ALEC) | 2025-12-31 | $5.72M | +5.8% |
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | $287.0K | +394.8% |
Compare CCCC, XFOR, DTIL, KYMR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗